CyberCare (Boynton Beach, Florida) signed an agreement with CyberAmeriCare (Palm Beach, Florida) a health care information technology company, for exclusive marketing, distribution and licensing rights to the CyberCare System in Central and South America as well as North America. CyberAmeriCare will be capitalized with $30 million in equity by parties other than CyberCare. As part of the agreement, following the capitalization, CyberAmeriCare is obligated to pay $15 million to CyberCare for the marketing, licensing, and distribution rights, subject to a unit sales requirement to retain exclusivity. An order for $500,000 of Electronic Housecall units accompanied the signing of the agreement. CyberCare is a network-based telehealth solutions company improving the delivery of care through its Internet-based technology.

Gyrus ENT (Memphis, Tennessee), formerly Smith & Nephew ENT and Somnus Medical, and Genzyme Biosurgery (Cambridge, Massachusetts), a division of Genzyme, have entered into an exclusive five-year agreement for the distribution of several of Genzyme's Sepra products for use in ear, nose and throat procedures. Gyrus ENT will market and sell Sepragel Sinus Bioresorbable Nasal Packing and Sinus Stent and Seprapack Bioresorbable Nasal Packing and Sinus Stent. The two products are formulations of hyaluronan (HA or hyaluronic acid) and are intended for use as postoperative nasal and sinus packing to separate traumatized tissues, control minimal bleeding and enhance patient care in the more than 360,000 functional endoscopic sinus surgery procedures performed worldwide on an annual basis. The agreement between Gyrus and Genzyme also extends to other potential ENT applications of hyaluronan. Gyrus ENT is a division of UK-based Gyrus Group.

Haemonetics (Braintree, Massachusetts) said that the American Red Cross (Washington) has contracted to use the company's latest blood freezing technology, the ACP 215 system, to expand its frozen blood storage capability. The Red Cross agreed to purchase 30 Haemonetics systems. No other terms of the agreement were disclosed. Haemonetics' system enables the freezing of red blood cells for up to 10 years and when needed, thawing those cells. The technology automates the blood freezing process in a closed system, which allows for 14-day storage of the thawed red blood cells. The ACP 215 system was given 510(k) clearance by the FDA in May.

Med-Design (Ventura, California), a maker of safety-engineered needle products for medical use, has reached an agreement with Owens-Illinois (O-I; Toledo, Ohio) for O-I to manufacture Med-Design's Safety Pre-filled Cartridge Injector. Med-Design will provide its Safety Pre-filled Cartridge Injector to potential pharmaceutical partners as part of a previously signed co-promotion agreement with Abbott Laboratories (Abbott Park, Illinois). As such, Med-Design has responsibility for delivering the safety cartridge injector to potential customers. OI makes medical packaging and other health care products.

Nellcor (Pleasanton, California) and Optical Sensors (Minneapolis, Minnesota) have entered into an exclusive worldwide licensing and distribution agreement for Optical Sensors' CapnoProbe product and technology. The agreement, under which Optical Sensors will receive royalties on future sales and certain milestone payments, is effective immediately. Specific financial terms were not disclosed. The CapnoProbe system is a hand-held device with an optical carbon dioxide (CO₂) probe that is slipped under the tongue like a thermometer. It measures the carbon dioxide tissue of the mouth's mucous membrane. According to the company, this measurement can assist physicians in diagnosing systemic hypoperfusion, an early indicator of impending or actual circulation collapse. The licensing agreement with Nellcor encompasses the current CapnoProbe system, as well as ongoing sensor and monitor development for the next-generation system. Nellcor will also assume all manufacturing and distribution of the CapnoProbe system. Nellcor makes pulse oximetry, fetal pulse oximetry and airway management products.

Steris (Mentor, Ohio) has signed a new expanded three-year agreement with General Electric Clinical Services (GECSI), a division of GE Medical Systems (Waukesha, Wisconsin). Steris will be GECSI's exclusive service provider in the U.S. for infection prevention and decontamination equipment. Steris estimates the revenue potential of this new agreement at more than $11 million annually, more than double that of the previous agreement. Steris will provide GECSI with all-inclusive services for repair and preventive maintenance. The agreement covers the servicing of all infection prevention and decontamination equipment manufactured by Steris, as well as equipment manufactured by many of its competitors.

SurgiLight (Orlando, Florida) has signed another exclusive distribution agreement with EnVision Technologies (Vancouver, British Columbia), to sell its IR-3000 in Mexico and the Caribbean. The IR-3000 is intended to treat a variety of ophthalmic conditions including presbyopia. The distributor has committed to purchase approximately $3 million in systems over the next three years, resulting in an additional $3.5 million in recurring income for SurgiLight over the same period.